Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Program of Surufatinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04814732
Expanded Access Status : Available
First Posted : March 24, 2021
Last Update Posted : April 28, 2021
Sponsor:
Information provided by (Responsible Party):
Hutchison Medipharma Limited

Brief Summary:
This treatment protocol is intended to provide early access of surufatinib to patients with locally advanced or metastatic NETs for whom, in the opinion of their treating physician, other treatment options or surufatinib clinical trials in this indication are unsuitable. This EAP is currently available in the US only.

Condition or disease Intervention/treatment
Neuroendocrine Tumors Drug: Surufatinib

Detailed Description:

Prior to any assessments, all subjects must provide a signed ICF. Prior to inclusion in the program, the patients must undergo all appropriate screening procedures to check for eligibility.

Once eligibility is confirmed, patients will receive treatment with surufatinib 300mg, orally (PO), daily (QD). All patients will undergo continuous monitoring for safety until the end of treatment.

There is no pre-defined duration of treatment for each patient. Patients will be treated until progressive disease (as defined by treating physician), unacceptable toxicity, death, withdrawal from program, the treatment becomes commercially available, or halting of product development.

A follow-up clinic visit is recommended for all patients approximately 30 days after last dose of treatment to complete the final safety assessments, as applicable.

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients, Treatment IND/Protocol
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: An Expanded Access Program of Surufatinib for Patients With Advanced or Metastatic Neuroendocrine Tumors



Intervention Details:
  • Drug: Surufatinib
    HMP-012

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  1. Histologically or cytologically documented, well differentiated, locally advanced or metastatic NETs
  2. The patient or parent/legal guardian (as appropriate) is willing and able to provide informed consent, and where required, the patient is willing to provide assent
  3. ≥12 years of age
  4. In the opinion of the patient's treating physician, other treatment options or clinical trials in this indication are unsuitable
  5. Patient has adequate bone marrow and organ function
  6. Urine dipstick ≤1+ for proteinuria or ≤30 mg/dL in urinalysis,
  7. ECOG ≤2 for adult patients (≥18 years of age), Karnofsky ≥60 for patients >16 and <18 years of age, and Lansky ≥60 for pediatric patients ≤16 years of age
  8. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and partner) to use a highly effective form(s) of contraception

Exclusion Criteria:

  1. Uncontrollable hypertension, as defined by local institution
  2. Gastrointestinal disease or condition that the physician suspects may affect drug absorption
  3. History or presence of a serious hemorrhage
  4. Clinically significant cardiovascular disease
  5. Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy
  6. High risk of bleeding at screening due to tumor invasion
  7. Arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing or thromboembolic events (including stroke and/or transient ischemic attack) within 6 months prior to first dosing
  8. Received treatment with anticancer therapy, including investigational therapy, within 7 days or 5 half-lives (whichever is longer)
  9. Received prior treatment with surufatinib
  10. Inability to take medication orally
  11. Any other clinically significant comorbidities that, in the judgment of the treating physician, could predispose the patient to safety risks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04814732


Contacts
Layout table for location contacts
Contact: Leslie Callahan, BSN,MS +1 973-826-5578 ExpandedAccess@hmplglobal.com
Contact: Monica Gonzalez, MS 210-508-5059 Monica.Gonzalez@syneoshealth.com

Sponsors and Collaborators
Hutchison Medipharma Limited
Investigators
Layout table for investigator information
Study Chair: John Kauh, MD Hutchison Medipharma Limited
Layout table for additonal information
Responsible Party: Hutchison Medipharma Limited
ClinicalTrials.gov Identifier: NCT04814732    
Other Study ID Numbers: 2020-012-GLOB3
First Posted: March 24, 2021    Key Record Dates
Last Update Posted: April 28, 2021
Last Verified: February 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue